Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Spongosine** (2-methoxyadenosine, CAS 24723-77-1) is a naturally occurring purine nucleoside analog isolated from marine sponges, particularly the Tethyidae family and Cryptotethya crypta. It functions as an antagonist of adenosine receptors (A1, A2A, A3), exhibiting diverse bioactivities including anti-inflammatory effects, analgesic properties, and vasodilation. As a research compound, it has shown potential antitumor activity against indolent lymphoid malignancies typical of purine nucleoside analogs, though it remains preclinical without approved indications.[1][3][7][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spongosine.